Mumbai: Pharma major Lupin Limited (Lupin) announced that it has successfully concluded the third edition of its series of medical symposiums for the Indian urology community. The latest edition, titled Masterclass: Best of EAU19, was organised in collaboration with the European Association of Urology (EAU) across four cities — Mumbai, New Delhi, Chennai and Kolkata — from December 18-22, 2019 and saw an impressive turnout of 550 urologists in attendance. It also marked the second consecutive year of Lupin’s collaboration with the EAU for organising the Masterclass.
This Masterclass leveraged the best of the Annual EAU Congress and enabled discussions around the latest clinical practices and key innovations in the field of urology. It also acquainted urology practitioners in India with the advancements made globally in this field and shared ideas to apply new best practices for patients in India.
Speakers at the event included globally renowned specialists such as Prof. Christopher Chapple from Sheffield U.K., an expert in functional urology; Prof. Marko Babjuk from Charles University, Prague, Cezch Republic; Prof. Maarten Albersen, Assistant Professor and adjunct head of clinic in Urology, University Hospitals Leuven; and Prof. Nikolaos Grivas, Netherlands Cancer Institute, Department of Urology.
About European Association of Urology (EAU)
The European Association of Urology (EAU) is a non-profit organisation which supports medical professionals working in the field of urology through many of its scientific, professional, educational and awareness-building initiatives. The overarching mission is to raise the level of urological care in Europe, and for many years this has been done through educational and scientific programmes aimed at urologists. Today the EAU represents more than 18,000 medical professionals working in Europe and beyond its borders. For more details see www.uroweb.org
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2019).
For the financial year ended March 31, 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on LinkedIn and Facebook at https://www.linkedin.com/company/lupinglobal/ and https://www.facebook.com/LupinWorld/ respectively.
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055
For further information or queries please contact:
Head – Investor Relations and M&A / Corporate Communications
Ph : +91 22 66408237